Inari Medical Inc. (NARI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Inari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Inari Medical, Inc. (NARI) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
Bronstein, Gewirtz & Grossman, LLC Encourages Inari Medical, Inc. (NARI) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
NARI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Inari Medical, Inc. and Encourages Investors to Contact the Firm
NEW YORK CITY, NY / ACCESSWIRE / December 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.
NARI Stock Likely to Gain Following Reimbursement Approval in Japan
Inari Medical announces reimbursement approval for ClotTriever Thrombectomy System in Japan and a new distribution partnership with Medikit.
Inari Medical Q3 Earnings Miss Estimates, Revenues Increase Y/Y
NARI's third-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.
Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Transcript
Inari Medical, Inc. (NASDAQ:NARI ) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET Company Participants Marissa Bych - VP, IR Drew Hykes - President and CEO Kevin Strange - CFO Tom Tu - Chief Medical Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG David Rescott - Baird Chris Pasquale - Nephron Research Stephanie Piazzola - Bank of America Lei Huang - Wells Fargo Zachary Day - Canaccord Genuity Michael Sarcone - Jefferies Ravi Misra - Truist Securities Matthew Blackman - Stifel Operator Good day, and welcome to the Inari Medical Third Quarter 2024 Earnings Call. [Operator Instructions] Also, please be aware that today's call is being recorded.
Inari Medical, Inc. (NARI) Reports Q3 Loss, Tops Revenue Estimates
Inari Medical, Inc. (NARI) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.05 per share a year ago.
Analysts Estimate Inari Medical, Inc. (NARI) to Report a Decline in Earnings: What to Look Out for
Inari Medical (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inari Medical Inc (NARI) Shares Up 3.22% on Oct 2
Shares of Inari Medical Inc (NARI, Financial) surged 3.22% in mid-day trading on Oct 2. The stock reached an intraday high of $42.21, before settling at $41.94, up from its previous close of $40.63.
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
